Skip to content

Built on BactPac™

A first-in-class therapeutic pipeline.

SiVEC is developing programs across cancer, respiratory disease, and genetic disease. Each program pairs the BactPac intracellular delivery platform with a therapeutic cargo selected for a specific disease.

Development pipeline

Focused programs. Visible progress.

The pipeline below highlights selected SiVEC programs across stages of development. Additional programs remain in discovery.

Program

CANCER

Asset

SVC-KRAb

Indication

RAS-mutant solid tumors

Progress: IND-enabling

DiscoveryPreclinical POCIND-enablingClinical

Program

CANCER

Asset

SVC-Survivin

Indication

Solid tumors

Progress: Preclinical proof of concept

DiscoveryPreclinical POCIND-enablingClinical

Program

INFECTIOUS DISEASE

Asset

SiVEC-IAV

Indication

Influenza A Virus

Progress: Preclinical proof of concept

DiscoveryPreclinical POCIND-enablingClinical

Supporting science

Follow the evidence behind the platform.

The Science page summarizes the preclinical evidence supporting BactPac delivery and program activity.

Explore the science →

Lead programs

Therapeutics enabled by intracellular access.

BactPac is designed to deliver therapeutic cargo inside target cells, enabling programs directed at intracellular disease biology.

Cancer

SVC-KRAb™

Pan-RAS biotherapeutic

SVC-KRAb™ is a BactPac-based therapeutic designed to deliver an intracellular biologic that inhibits cancer-driving RAS signaling.

The program is being developed for RAS-mutant solid tumors, including pancreatic, colorectal, and lung cancers.

Program advantages

  • Targets cancer-driving RAS inside tumor cells
  • Designed for activity across multiple RAS mutations
  • Uses BactPac to produce and deliver the therapeutic payload

Up to 80%

tumor-growth reduction in vivo

Preclinical evidence

SVC-KRAb has shown activity across multiple RAS-driven cancer models.

SVC-Survivin™

Survivin-targeting therapeutic

SVC-Survivin™ is a BactPac-based therapeutic designed to deliver an intracellular antibody that blocks survivin, a protein that helps cancer cells resist programmed cell death.

Program advantages

  • Targets an intracellular cancer pathway
  • Designed to increase sensitivity to chemotherapy
  • Supports multiple intracellular payload formats

Preclinical evidence

A proof-of-concept study demonstrated intracellular antibody delivery and increased chemotherapy sensitivity in vitro.

Respiratory disease

SiVEC-IAV™

Inhaled antiviral

SiVEC-IAV™ is an inhaled BactPac-based antiviral designed to deliver RNA payloads that suppress influenza A replication in respiratory cells.

Program advantages

  • Direct delivery to respiratory tissues
  • Targets conserved influenza A sequences
  • Designed for broad activity across viral strains

Preclinical evidence

SiVEC-IAV reduced influenza replication in preclinical respiratory models.

Platform partnerships

BactPac is built to enable more than our own pipeline.

Alongside additional internal discovery programs, SiVEC is excited to partner with biopharma teams to pair BactPac with new therapeutic cargos and advance programs across disease areas.